The National Comprehensive Cancer Network has concluded its 2021 Patient Advocacy Summit, which focused on expanding precision medicine in order to improve cancer outcomes, featuring discussions on federal and local policies to broaden genetic/genomic testing access.
Breast, bladder, and pancreatic cancers are increasingly being treated with a broad range of therapies before a patient undergoes surgery, and cancer stage at diagnosis continues to be a leading factor in determining a person’s survival rate for all types of cancer, according to the first-ever annual cancer report from the National Cancer Database.
